ATE72975T1 - Arzneimittel mit gesteuerter absorption. - Google Patents

Arzneimittel mit gesteuerter absorption.

Info

Publication number
ATE72975T1
ATE72975T1 AT87305484T AT87305484T ATE72975T1 AT E72975 T1 ATE72975 T1 AT E72975T1 AT 87305484 T AT87305484 T AT 87305484T AT 87305484 T AT87305484 T AT 87305484T AT E72975 T1 ATE72975 T1 AT E72975T1
Authority
AT
Austria
Prior art keywords
core
verapamil
polymeric material
powder mixture
controlled absorption
Prior art date
Application number
AT87305484T
Other languages
English (en)
Inventor
Edward James Geoghegan
Donald Eugene Panoz
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11030118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE72975(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Application granted granted Critical
Publication of ATE72975T1 publication Critical patent/ATE72975T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT87305484T 1986-06-20 1987-06-19 Arzneimittel mit gesteuerter absorption. ATE72975T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE166186A IE58401B1 (en) 1986-06-20 1986-06-20 Controlled absorption pharmaceutical composition
EP87305484A EP0250267B1 (de) 1986-06-20 1987-06-19 Arzneimittel mit gesteuerter Absorption

Publications (1)

Publication Number Publication Date
ATE72975T1 true ATE72975T1 (de) 1992-03-15

Family

ID=11030118

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87305484T ATE72975T1 (de) 1986-06-20 1987-06-19 Arzneimittel mit gesteuerter absorption.

Country Status (10)

Country Link
US (1) US4863742A (de)
EP (1) EP0250267B1 (de)
JP (1) JP2637981B2 (de)
AT (1) ATE72975T1 (de)
AU (1) AU599385B2 (de)
DE (1) DE3776982D1 (de)
ES (1) ES2039440T3 (de)
GR (1) GR3003978T3 (de)
IE (1) IE58401B1 (de)
PH (1) PH23993A (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
DE3856555T2 (de) * 1987-10-16 2004-04-29 Elan Corp. Plc Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
JPH0791184B2 (ja) * 1988-03-31 1995-10-04 田辺製薬株式会社 放出制御型製剤およびその製法
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
CH678920A5 (de) * 1989-11-14 1991-11-29 Gergely Gerhard
JPH0463196A (ja) * 1990-06-30 1992-02-28 Kyodo:Kk 流体処理装置
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
IT1291652B1 (it) * 1997-04-24 1999-01-19 Apr Trading Sa Composizioni farmaceutiche a copertura terapeutica programmata
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
WO2001054671A1 (fr) * 2000-01-27 2001-08-02 Tanabe Seiyaku Co., Ltd. Preparation a liberation prolongee et son procede de fabrication
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
KR20040047747A (ko) 2001-03-13 2004-06-05 펜웨스트 파머슈티칼즈 컴파니 변시치료 제형
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US20030228368A1 (en) * 2001-09-28 2003-12-11 David Wynn Edible solid composition and dosage form
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
MXPA04002973A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
WO2005027843A2 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
EA200600598A1 (ru) * 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US20060003001A1 (en) * 2004-02-11 2006-01-05 John Devane Chronotherapeutic compositions and methods of their use
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (en) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) * 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20090214643A1 (en) * 2005-07-19 2009-08-27 Franklin Amie E Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
US20070077300A1 (en) 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
CA2628031C (en) 2005-11-10 2013-03-05 Circ Pharma Research And Development Limited Once-daily administration of central nervous system drugs
JP5433236B2 (ja) * 2006-01-27 2014-03-05 アプタリス ファーマテック，インコーポレイテッド 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
US20070196491A1 (en) * 2006-01-27 2007-08-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20070286903A1 (en) * 2006-06-13 2007-12-13 Becicka Brian T Composition and method for taste masking
EP2069021A2 (de) * 2006-08-04 2009-06-17 AGI Therapeutics Research Limited Verfahren zur behandlung mindestens eines leidens mit mt1-rezeptor, 5ht2b-rezeptor- und l-calciumkanal-aktivität
ES2651444T3 (es) 2006-10-20 2018-01-26 Johnson & Johnson Consumer Inc. Combinación de acetaminofeno con ibuprofeno para el tratamiento del dolor
CA2677076C (en) * 2007-03-02 2017-09-12 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US20080317677A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
RU2010119041A (ru) 2007-10-12 2011-11-20 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
AU2008318851B2 (en) * 2007-10-31 2014-04-17 Mcneil-Ppc, Inc. Orally disintegrated dosage form
EP2227226B1 (de) * 2007-12-21 2016-10-26 Johnson & Johnson Consumer Inc. Herstellung einer tablette
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
RU2011102777A (ru) * 2008-06-26 2012-08-10 МакНЕЙЛ-ППС, ИНК. (US) Частицы с покрытием, содержащие фармацевтически активные агенты
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US8784781B2 (en) 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
RU2712267C2 (ru) 2014-01-10 2020-01-28 Джонсон энд Джонсон Консьюмер Инк. Способ изготовления таблеток с использованием радиочастотного излучения и частиц с поглощающим покрытием
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3113901A1 (de) * 1981-04-07 1982-10-28 Basf Ag, 6700 Ludwigshafen Wirkstoffzubereitung zur oralen applikation
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
IE56151B1 (en) * 1983-10-20 1991-05-08 Elan Corp Plc Tablet formulation
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation

Also Published As

Publication number Publication date
PH23993A (en) 1990-02-09
AU7452887A (en) 1987-12-24
JP2637981B2 (ja) 1997-08-06
EP0250267B1 (de) 1992-03-04
US4863742A (en) 1989-09-05
DE3776982D1 (de) 1992-04-09
JPS635021A (ja) 1988-01-11
ES2039440T3 (es) 1993-10-01
EP0250267A3 (en) 1988-08-10
AU599385B2 (en) 1990-07-19
GR3003978T3 (de) 1993-03-16
IE58401B1 (en) 1993-09-08
EP0250267A2 (de) 1987-12-23

Similar Documents

Publication Publication Date Title
DE3776982D1 (de) Arzneimittel mit gesteuerter absorption.
ATE128863T1 (de) Arzneimittelformulierungen mit verzögerter wirkstoffabgabe.
DE68907762D1 (de) Arzneizubereitung mit gesteuerter wirkstofffreisetzung und verfahren zu deren herstellung.
NO884947L (no) Fremgangsmaate for fremstilling av farmasoeytisk doseringsform med kontrollert frigjoerelse.
AU6764390A (en) Pharmaceutical granules and drug dosage units made therefrom
CY1764A (en) New drug preparation with controlled release of the active compound, and a method for the manufacture thereof
FI885460L (fi) Menetelmä suun kautta annettavaksi tarkoitetun, aktiiviyhdistettä kontrolloidusti vapauttavan farmaseuttisen formulaation valmistamiseksi
DE69213800D1 (de) Oral anzuwendende magensaftstabile Arzneimittel mit gesteuerter Wirkstoffabgabe enthaltend Gallensäuren und deren Salze
ATE126055T1 (de) Naproxen-formulierung zur kontrollierten absorption zur einmal täglichen anwendung.
ATE87201T1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
DE3856555D1 (de) Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
SE8803822D0 (sv) Novel dosage form
DE3856258D1 (de) Verfahren zur Herstellung eines Retardpräparates, das Diltiazem in einer einzigen Tagesdosis enthält
EP0425298A3 (en) Sustained-release preparation of basic medical agent hydrochloride
FI871116A0 (fi) Kontrollerbart frigoerande nifedipinprodukter.
DE3789258D1 (de) Multigranuläre Tablette mit verzögerter Freisetzung.
ATE24664T1 (de) Arzneimittel mit programmierter abgabe, assoziierend acetylsalicylsaeure mit dihydroergotamine.
EP0362731A3 (de) Verfahren zur Herstellung von Arzneimittelwirkstoff-Partikeln mit verbesserten Fliess-, Lager- und Formulierungseigenschaften sowie Arzneimittel, die diese Arzneimittelwirkstoff-Partikeln enthalten
JPS56123912A (en) Drug-containing tape preparation
BE895805A (fr) Nouvel heptadecapeptide a effet de liberation d'hormone de croissance et medicament le contenant
JPS55133315A (en) Curing and preventive agent for digestive ulcer

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time